A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Abemaciclib (Primary) ; Lodapolimab (Primary) ; LY 3321367 (Primary) ; Merestinib (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Intestinal cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms PACT
- Sponsors Eli Lilly and Company
- 26 Sep 2024 Status changed from active, no longer recruiting to completed.
- 18 Apr 2024 Planned End Date changed from 29 Mar 2024 to 1 Jul 2024.
- 05 Dec 2023 Planned End Date changed from 6 Dec 2023 to 29 Mar 2024.